phrykt

Bicara Therapeutics Inc. (BCAX): who owns it and who trades it

As of Nov 16, 2026, BCAX insiders reported 57 open-market sales worth $9.9M and 1 purchase worth $4.8M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ryan Cohlhepp (President), with $3.5M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Bicara Therapeutics

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BCAX

172 funds and institutions reported BCAX shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 11.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Ra Capital Management, L.P.11.1%
T. Rowe Price Investment Management, Inc.9.7%
Siren, L.L.C.8.6%
Vestal Point Capital, LP8.0%
Deep Track Capital, LP6.3%
BlackRock, Inc.5.9%
Jupiter Topco LLC4.8%
Red Tree Management, LLC4.8%
Tpg Gp A, LLC4.6%
Vanguard Capital Management LLC3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.7.26M11.08%$215MNo change
T. Rowe Price Investment Management, Inc.6.34M9.68%$188M-4%
Siren, L.L.C.5.60M8.56%$166M-3%
Vestal Point Capital, LP5.25M8.02%$156M-3%
Deep Track Capital, LP4.10M6.26%$122M+1%
BlackRock, Inc.3.85M5.88%$114M+35%
Jupiter Topco LLC3.17M4.84%$94M–
Red Tree Management, LLC3.16M4.83%$93.9M-0%
Tpg Gp A, LLC3.01M4.60%$89.4MNo change
Vanguard Capital Management LLC2.22M3.39%$65.8M+25%
State Street Corp2.05M3.13%$60.8M+44%
Franklin Resources Inc1.95M2.98%$58M+20%
T. Rowe Price Associates1.90M2.91%$56.5M+38%
FMR LLC (Fidelity)1.89M2.89%$56.2M-10%
Omega Fund Management, LLC1.82M2.78%$54.1M-24%
Geode Capital Management, LLC1.16M1.78%$34.5M+40%
California State Teachers Retirement System1.16M1.77%$39M+6742%
JPMorgan Chase & Co1.02M1.55%$29.8M–
Jones Hill Capital LP892,6211.36%$26.5M-29%
Acorn Capital Advisors, LLC643,3810.98%$19.1MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BCAX insiders reported $4.8M of open-market purchases and $9.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$4.8M
1 trades, 1 people
Sales, 12 months
$9.9M
57 trades, 4 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Sep 8, 2026
Filed Sep 10, 2026

Purchases and sales by month

$4.8M$4.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 8, 2026Ryan CohlheppCEOSale plan3,442$23.43$80.6KForm 4
Sep 8, 2026Ryan CohlheppCEOSale plan14,058$22.77$320KForm 4
Aug 10, 2026Ivan HyepCFOSale plan12,500$27.97$350KForm 4
Aug 10, 2026Claire MazumdarCEOSale plan10,000$27.98$280KForm 4
Aug 10, 2026Ryan CohlheppPresidentSale plan18,750$27.98$525KForm 4
Jul 10, 2026Claire MazumdarCEOSale plan9,972$28.42$283KForm 4
Jul 10, 2026Claire MazumdarCEOSale plan28$29.68$831Form 4
Jul 9, 2026Ryan CohlheppPresidentSale plan536$29.00$15.5KForm 4
Jul 8, 2026Ryan CohlheppPresidentSale plan22,833$28.76$657KForm 4
Jul 8, 2026Ryan CohlheppPresidentSale plan1,075$30.35$32.6KForm 4
Jul 8, 2026Ryan CohlheppPresidentSale plan4,306$29.80$128KForm 4
Jul 8, 2026Ivan HyepCFOSale plan830$30.31$25.2KForm 4
Jul 8, 2026Ivan HyepCFOSale plan22,757$28.60$651KForm 4
Jul 8, 2026Ivan HyepCFOSale plan4,413$29.82$132KForm 4
May 21, 2026Ivan HyepCFOSale plan9,200$20.42$188KForm 4
May 18, 2026Claire MazumdarCEOSale plan12,022$19.96$240KForm 4
May 18, 2026Claire MazumdarCEOSale plan2,978$20.35$60.6KForm 4
May 15, 2026Ryan CohlheppPresidentSale plan8,000$20.29$162KForm 4
May 15, 2026Ryan CohlheppPresidentSale plan4,500$20.29$91.3KForm 4
Apr 27, 2026David RabenChief Medical OfficerSale plan5,500$22.88$126KForm 4
Apr 21, 2026Ivan HyepCFOSale plan9,200$23.00$212KForm 4
Apr 20, 2026Claire MazumdarCEOSale plan15,000$23.61$354KForm 4
Apr 15, 2026Ryan CohlheppPresidentSale plan4,500$23.01$104KForm 4
Apr 15, 2026Ryan CohlheppPresidentSale plan8,000$23.01$184KForm 4
Mar 25, 2026David RabenChief Medical OfficerSale plan5,500$18.95$104KForm 4
Mar 23, 2026Ivan HyepCFOSale plan9,200$18.52$170KForm 4
Mar 20, 2026Claire MazumdarCEOSale plan1,596$18.95$30.2KForm 4
Mar 19, 2026Claire MazumdarCEOSale plan6,905$18.78$130KForm 4
Mar 18, 2026Claire MazumdarCEOSale plan6,499$18.84$122KForm 4
Mar 16, 2026Ryan CohlheppPresidentSale plan8,000$19.66$157KForm 4
Mar 16, 2026Ryan CohlheppPresidentSale plan4,500$19.66$88.5KForm 4
Mar 9, 2026Claire MazumdarCEOSale plan36,766$19.17$705KForm 4
Mar 6, 2026Claire MazumdarCEOSale plan3,817$18.75$71.6KForm 4
Mar 5, 2026Claire MazumdarCEOSale plan1,786$18.74$33.5KForm 4
Mar 4, 2026Claire MazumdarCEOSale plan2,631$18.73$49.3KForm 4
Mar 4, 2026Ivan HyepCFOSale plan2,963$18.25$54.1KForm 4
Mar 4, 2026David RabenChief Medical OfficerSale plan16,300$18.52$302KForm 4
Mar 3, 2026Ryan CohlheppPresidentSale plan12,892$18.16$234KForm 4
Mar 3, 2026Ryan CohlheppPresidentSale plan4,500$18.16$81.7KForm 4
Mar 3, 2026Ivan HyepCFOSale plan13,555$18.22$247KForm 4
Mar 3, 2026David RabenChief Medical OfficerSale plan200$18.45$3.7KForm 4
Feb 26, 2026Ra Capital Management, L.P. +4DirectorPurchase300,000$16.00$4.8MForm 4
Feb 25, 2026Ryan CohlheppPresidentSale plan3,108$18.04$56.1KForm 4
Feb 25, 2026Ryan CohlheppPresidentSale plan523$18.04$9.4KForm 4
Jan 22, 2026Ryan CohlheppPresidentSale plan3,828$18.10$69.3KForm 4
Jan 22, 2026Ivan HyepCFOSale plan1,882$18.15$34.2KForm 4
Jan 15, 2026Ryan CohlheppPresidentSale plan149$18.02$2.7KForm 4
Dec 22, 2025Ivan HyepCFOSale plan9,200$18.31$168KForm 4
Dec 15, 2025Ryan CohlheppPresidentSale plan4,500$18.68$84.1KForm 4
Dec 15, 2025Ryan CohlheppPresidentSale plan8,000$18.68$149KForm 4
Nov 25, 2025David RabenChief Medical OfficerSale plan906$18.84$17.1KForm 4
Nov 25, 2025David RabenChief Medical OfficerSale plan4,594$18.84$86.6KForm 4
Nov 24, 2025Ivan HyepCFOSale plan17,795$18.55$330KForm 4
Nov 24, 2025Claire MazumdarCEOSale plan41,163$18.86$776KForm 4
Nov 24, 2025David RabenChief Medical OfficerSale plan5,500$18.45$101KForm 4
Nov 21, 2025Ivan HyepCFOSale plan605$18.15$11KForm 4
Nov 21, 2025Ryan CohlheppPresidentSale plan4,500$18.05$81.2KForm 4
Nov 21, 2025Ryan CohlheppPresidentSale plan8,000$18.05$144KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ra Capital Management, L.P.Director, 10% owner$4.8M–Feb 26, 2026
Ryan CohlheppPresident and COO, Director–$3.5MSep 8, 2026
Claire MazumdarChief Executive Officer, Director–$3.1MAug 10, 2026
Ivan HyepChief Financial Officer–$2.6MAug 10, 2026
David RabenChief Medical Officer–$741KApr 27, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BCAX short interest

High short interest. 14.9% of BCAX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short barely changed.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.86M BCAX shares were sold short, 14.9% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 3.8 trading days (days to cover).

Shares short, % of all shares

14.9%May 15Oct 3017.3%

Days to cover

3.8May 15Oct 3025.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.86M14.90%-4%2.57M3.8
Oct 15, 202610.30M15.56%-4%893,32211.5
Sep 30, 202610.69M16.16%-4%753,20814.2
Sep 15, 202611.19M16.91%+3%496,02722.6
Aug 31, 202610.85M16.39%+4%491,10422.1
Aug 14, 202610.46M15.81%+9%787,82613.3
Jul 31, 20269.60M14.66%+3%469,96520.4
Jul 15, 20269.32M14.23%-8%734,24812.7
Jun 30, 202610.12M15.46%-0%1.38M7.3
Jun 15, 202610.16M15.52%+1%514,10419.8
May 29, 202610.08M15.40%+2%448,41922.5
May 15, 20269.85M15.04%+11%568,90817.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Bicara Therapeutics company events

Bicara Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 25, 2026AgreementBicara Therapeutics Inc. entered into a Sub-Sublease Agreement with Wayfair LLC, as sublandlord, pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located at 10 St. James Avenue, Boston, Massachusetts 02116. Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. Jul 28, 2026LeadershipKiran Mazumdar-Shaw resigned from the Board of Directors of Bicara Therapeutics Inc. and her position on the Nominating and Corporate Governance Committee of the Board, effective as of July 28, 2026. Filing
  5. Jun 10, 2026VoteReported shareholder vote results. Filing
  6. May 21, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC.” A copy of the press release is attached hereto as Exhibit 99.1 and is… Filing
  7. May 11, 2026ResultsReleased financial results. Filing
  8. Mar 30, 2026ResultsReleased financial results. Filing
  9. Feb 26, 2026AgreementBicara Therapeutics Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of (i) 7,175,000 shares of its… Filing
  10. Feb 19, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein… Filing
  11. Jan 12, 2026AnnouncementBicara Therapeutics Inc. issued a press release entitled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
  12. Dec 8, 2025AnnouncementThe Company announced preliminary data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic head and neck squamous cell carcinoma. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Bicara Therapeutics financials

Famous investors that hold BCAX

4 of the 50 well-known investors we track reported holding BCAX in their latest 13F filing. The largest position is Ken Griffin's, worth $19.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.03M$19.2M0.0%+388%
Steve Cohen · Point72 Asset ManagementQ3 2026627,108$11.7M0.0%New
Israel Englander · Millennium ManagementQ3 2026591,022$11M0.0%+125%
Paul Tudor Jones · Tudor Investment CorpQ3 202633,086$616K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BCAX in the last 120 days.

FiledHolderFormStake
Oct 7, 2026T. Rowe Price Investment Management, Inc.13G/A4.2%
Oct 7, 2026T. Rowe Price Investment Management, Inc.13G/A4.2%

Questions about Bicara Therapeutics Inc. (BCAX) stock

Who owns the most BCAX stock?

The largest reported owner of Bicara Therapeutics Inc. (BCAX) is Ra Capital Management, L.P., with 11.1% of the company. In total, 172 funds and institutions reported holding BCAX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BCAX insiders buying or selling?

In the last 12 months, BCAX insiders reported 1 open-market purchase worth $4.8M and 57 sales worth $9.9M. The latest trade was on Sep 8, 2026. See every trade.

What is the short interest in BCAX?

As of Oct 30, 2026, 9.86M BCAX shares were sold short, 14.9% of the shares outstanding, down 4.2% from the report before. At the average daily volume of 2.57M shares, buying them all back would take about 3.8 trading days (days to cover). See the history.

Which famous investors hold BCAX?

4 of the 50 well-known investors we track reported BCAX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $19.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.